Bracket Email Encryption by Mailprotector
Bracket by Mailprotector simplifies email encryption by allowing users to secure messages effortlessly just by wrapping the email subject in brackets, eliminating the need for passwords or additional apps, thereby enhancing compliance and security with seamless integration into existing email clients.
Painless email encryption.
Just [wrap the subject in brackets] and send. Bracket handles everything else—no passwords, no apps, no friction.
See why people BracketGet a demo
What makes Bracket better?
Encryption was a pain
Install this app. Create an account. Don't forget another password. The steps pile up until someone decides it's easier to just send a normal email. So they do.
So we fixed it
Bracket was built around one idea: encryption should feel like sending any other email. We removed the complexity, kept the security, and never looked back.
The payoff for MSPs
When encryption is this easy, people love using it. Compliance happens naturally, sensitive data stays where it belongs, and password reset tickets disappear.
See what we did
Finally, email encryption that works for everyone
The Trigger
Bracket the subject
Wrap the [subject] in brackets to encrypt. That's the only thing anyone needs to learn.
Compose the message
Write the email content from your go-to email client and device. With Bracket, you don't have to choose.
Send securely
Hit send. Bracket intercepts the message in transit and encrypts it automatically.
Send Sent
BIU
To
Subject
[]
9:41
Cancel Sent
Subject:
[]
New secure message: [Test Results – Confidential]
You received a secure message from:
Dr. Amara Shalobi, MD
Board-Certified Oncologist
Foothills Cancer Care Associates
View message
Dr. Amara Shalobi sent you a message with Bracket. Tap the button above to securely view the message.
This button will only work from this device and will expire after 15 minutes. Once it has expired you'll need to sign in to view your message.
Important: Do not reply to this notification. To send an encrypted response, view the message and securely reply from there.
REPLY
[
Your Test Results – Confidential Medical Information
]
Dr. Amara Shalobi, Mar 18th 2026 at 11:35 am
2Recipients
Hi John,
It was really good seeing you last week — I hope you're starting to feel a bit more like yourself. I wanted to get these test results from March 11th over to you as soon as I could. Please take a moment to look everything over, and don't hesitate to reach out with any questions.
Patient: John Doe
Date of Birth: June 14, 1971
Patient ID: GCC-204917
Ordering Physician: Dr. Amara Shalobi, MD, Oncology
Tests Ordered: CT Scan (Chest/Abdomen/Pelvis), CBC with Differential, Tumor Marker Panel (CEA, CA 19-9)
Summary of Findings:
The CT scan conducted on March 11, 2026 revealed a 2.3 cm soft tissue mass in the lower lobe of the right lung, consistent with findings from your prior imaging. There is no evidence of lymph node involvement or distant metastasis at this time.
Your CBC results were within normal range, with no significant abnormalities noted. Your CEA level returned at 8.4 ng/mL (reference range: 0–3.0 ng/mL), which remains elevated compared to your baseline. Your CA 19-9 level was within normal limits at 22 U/mL.
Assessment & Recommended Next Steps:
Based on these results, I recommend the following:
- Biopsy – A CT-guided needle biopsy of the right lung mass is strongly recommended to obtain tissue for pathological analysis and definitive diagnosis.
- Follow-up Appointment – Please schedule an in-office consultation within the next 7–10 days to discuss these findings in detail and review next steps.
- PET Scan – Pending biopsy results, a full-body PET scan may be ordered to further evaluate metabolic activity.
Please be aware that this email contains protected health information (PHI) and is intended solely for the named recipient. If you have received this message in error, please notify our office immediately and delete this email.
To schedule your follow-up, please call our office at (828) 555-0182 or reply to this message.
Warm regards,
Dr. Amara Shalobi, MD
Board-Certified Oncologist
Foothills Cancer Care Associates
828-555-0182 | [email protected]
Send me an encrypted message or file – bracket.email/drshalobi
0 Replies
Reply to this conversation
Recipients
Dr. Amara Shalobi, MD
Owner
J
John Doe
The Handoff
Effortless on arrival
Recipients access encrypted messages through a secure link delivered straight to their inbox. One click and they're in—no account and password creation required.
Links expire in 15 minutes, work only once, and are locked to the device that requested them so there's no sacrificing security for usability.
Bracket Share
Send files the same way you send encrypted email
Included with every Bracket license is our encrypted file transfer service, Bracket Share. Users get their own personalized file transfer page with a customizable Share link that's easy to remember and distribute.
Personalized invites
Send personalized invites with a profile attached so recipients feel more confident about sharing sensitive data.
Open to all, secured by design
Anyone can share encrypted files via your link. All senders are validated with inbox authentication to prevent abuse.
Arrives in the Bracket inbox
Encrypted files—up to 1GB, 25 files per share—show up in the Bracket inbox just like regular messages.
https://bracket.email/drshalobi
Share
Send a secure message to
Dr. Amara Shalobi, MD
Board-Certified Oncologist
Foothills Cancer Care Associates
Add files
Your email:
Message:
Send
Encryption is just the baseline
Bracket sets a higher security standard with protections traditional email encryption simply can't match.
Device Fingerprinting
Access links are tied to the originating device. Attempts from other devices are automatically blocked.
One-Time Links
Sign-in links expire after 15 minutes and can only be used once, preventing reuse from old messages.
Personal Data Key
Users can require a personal data key at sign-in for a zero-access boundary when circumstances require.
Key Management
Keys are geographically distributed and automatically rotated, eliminating single points of failure.
Multi-Factor Authentication
Users can enable multi-factor authentication at sign-in for an extra layer of identity verification.
AES-256 Encryption
All messages and files are encrypted using AES-256, keeping data unreadable in transit and at rest.
The Bracket Inbox
Your encrypted messages, always within reach.
The Bracket inbox opens in any browser on any device, giving you a clean, organized view of every encrypted conversation.
Compose encrypted messages directly from bracket.email
Compose encrypted messages from the secure portal
Customize settings to brand your messages and more
Your Test Results – Confidential Medical Information3/18/2026
Dear Mr. John Doe, I hope this message finds you wel
Share1 file shared
3/15/2026
MRI scan report enclosed – Doe, J. (03/14/26). Please review prior to...
RE: Biopsy scheduling – follow-up3/12/2026
Hi John, we've scheduled the biopsy for the week of March 17th. My coordinator will...
Prior Auth Request – Pembrolizumab3/10/2026
S. Rivera, Nurse Navigator
Hi Sarah, can you get the PA started for Mr. Henderson's Pembrolizumab? I've attached...
Share1 file shared
3/8/2026
Tissue analysis from 03/06 biopsy. EGFR mutation status and staging notes...
Tumor Board – March case presentation3/5/2026
Dr. Opara and Dr. Mensah 1
Dr. Opara, I'm submitting my case for the March 10th tumor board. Patient is John Doe...
Clinical Trial Consent – Thompson, M.3/3/2026
Hi Marcus, I've attached the KEYNOTE-789 consent materials for you to review before...
DraftReferral Letter – Doe, J.
3/1/2026
No recipients
...
Share2 files shared
2/28/2026
EOB summary and itemized billing for Doe, J. (Acct: GCC-204917) enclosed...
Follow-up Care Plan – Watkins, E.2/25/2026
Thank you for yesterday's consultation. Could you clarify the dosing schedule...
Patient Transfer Summary – Nguyen, J.2/22/2026
Transfer request enclosed. Nguyen, J. 58M Stage IIA NSCLC, referred for...
Share1 file shared
2/20/2026
CBC with differential results – Henderson, R. (02/19/26). WBC flagged for...
RE: Pembrolizumab side effects2/18/2026
Dr. Shalobi, I've been experiencing significant fatigue and joint pain since...
Surgical Consult Request – Doe, J.2/15/2026
Please review attached imaging prior to Thursday's multidisciplinary consult...
Share1 file shared
2/12/2026
Full-body PET scan – Doe, J. Metabolic activity findings attached for staging...
Treatment Plan Review – Q1 20262/10/2026
Dr. Patel and Dr. Mensah 3
Amara, can we align on the protocol adjustments before the next tumor board?...
Second Opinion Records – Reyes, C.2/8/2026
Forwarding complete records per patient request. Includes imaging, path, and...
DraftFollow-up Notes – Rodriguez, C.
2/5/2026
No recipients
...
Hospice Referral – Henderson, R.2/3/2026
Thank you for the referral. Our intake coordinator will reach out to the family...
Share1 file shared
1/30/2026
Comprehensive genomic profile – Watkins, E. BRCA2 variant detected. Full...
RE: KEYNOTE-789 eligibility – Reyes1/28/2026
Screening criteria reviewed. Reyes, C. meets all inclusion criteria for arm B...
1-25 of 452
Add new recipients to an existing encrypted message
Recall messages to revoke individual access
Export messages to your inbox
REPLY
[Your Test Results – Confidential Medical Information]
Dr. Amara Shalobi, Mar 18th 2026 at 11:35 am
2
Recipients
Hi John,
It was really good seeing you last week — I hope you're starting to feel a bit more like yourself. I wanted to get these test results from March 11th over to you as soon as I could. Please take a moment to look everything over, and don't hesitate to reach out with any questions.
Patient: John Doe
Date of Birth: June 14, 1971
Patient ID: GCC-204917
Ordering Physician: Dr. Amara Shalobi, MD, Oncology
Tests Ordered: CT Scan (Chest/Abdomen/Pelvis), CBC with Differential, Tumor Marker Panel (CEA, CA 19-9)
Summary of Findings:
The CT scan conducted on March 11, 2026 revealed a 2.3 cm soft tissue mass in the lower lobe of the right lung, consistent with findings from your prior imaging. There is no evidence of lymph node involvement or distant metastasis at this time.
Your CBC results were within normal range, with no significant abnormalities noted. Your CEA level returned at 8.4 ng/mL (reference range: 0–3.0 ng/mL), which remains elevated compared to your baseline. Your CA 19-9 level was within normal limits at 22 U/mL.
Assessment & Recommended Next Steps:
Based on these results, I recommend the following:
- Biopsy – A CT-guided needle biopsy of the right lung mass is strongly recommended to obtain tissue for pathological analysis and definitive diagnosis.
- Follow-up Appointment – Please schedule an in-office consultation within the next 7–10 days to discuss these findings in detail and review next steps.
- PET Scan – Pending biopsy results, a full-body PET scan may be ordered to further evaluate metabolic activity.
Please be aware that this email contains protected health information (PHI) and is intended solely for the named recipient. If you have received this message in error, please notify our office immediately and delete this email.
To schedule your follow-up, please call our office at (828) 555-0182 or reply to this message.
Warm regards,
Dr. Amara Shalobi, MD
Board-Certified Oncologist
Foothills Cancer Care Associates
828-555-0182 | [email protected]
Send me an encrypted message or file – bracket.email/drshalobi
0 Replies
Reply to this conversation
Recipients
Dr. Amara Shalobi, MD
Owner
J
John Doe
[MRI Scan Report – Doe, J.]
Piedmont Imaging Center, Mar 15th 2026 at 9:22 am
1
Reply
1
File
2
Recipients
Dr. Shalobi,
Attached is the MRI report for John Doe from his March 14th exam. The right lower lobe mass now measures 2.4 cm x 2.1 cm, up slightly from 2.3 cm on prior imaging. No lymphadenopathy or pleural effusion was identified.
Full report with images is included in the attachment. Please give us a call at (864) 555-0291 if you have any questions.
1 Reply
Dr. Amara Shalobi replied· Mar 15th 2026 at 2:10 pm
Thank you for sending this over. I've reviewed the scan — the interval growth is notable. I'll incorporate these findings into our treatment planning discussion ahead of the biopsy.
Reply to this conversation
1 File
Download all
MRI_Doe_J_20260314.pdf (3.2 MB)
Added by Piedmont Imaging Center on Mar 15th 2026 at 9:22 am
Recipients
G
Piedmont Imaging Center
Owner
Dr. Amara Shalobi, MD
[RE: Biopsy scheduling – follow-up]
Dr. Amara Shalobi, Mar 12th 2026 at 2:15 pm
2
Replies
2
Recipients
Hi John, I wanted to reach out with some scheduling info for the CT-guided biopsy. We've got you planned for the week of March 17th — my coordinator will follow up to confirm the exact date and send over prep instructions.
The procedure takes about an hour and most patients are back to their normal routine within a day or two. Please don't hesitate to call us at (828) 555-0182 if you have any questions before then.
2 Replies
J
John Doe replied· Mar 12th 2026 at 4:45 pm
Thank you, Dr. Shalobi. That's a relief to hear. We'll plan around the 17th and wait to hear from your coordinator.
Dr. Amara Shalobi replied· Mar 13th 2026 at 9:12 am
Great — we'll get the confirmation out to you shortly. Don't hesitate to call if anything comes up before then.
Reply to this conversation
Recipients
Dr. Amara Shalobi, MD
Owner
J
John Doe
[Prior Auth Request – Pembrolizumab]
Dr. Amara Shalobi, Mar 10th 2026 at 10:45 am
1
Reply
1
File
2
Recipients
Hi Sarah, can you get the prior authorization started for Mr. Henderson's first cycle of Pembrolizumab? I've attached the clinical notes you'll need. BlueCross BlueShield typically takes 5 to 7 business days, so we'd want to get this submitted by end of week to stay on schedule for his infusion.
Let me know if you need anything else from me to complete the form.
1 Reply
S
S. Rivera, RN replied· Mar 10th 2026 at 12:30 pm
On it. I'll have the form completed and ready for your signature by end of day. I'll send it back through here once it's ready.
Reply to this conversation
1 File
Download all
PA_Henderson_Pembrolizumab.pdf (1.1 MB)
Added by Dr. Amara Shalobi on Mar 10th 2026 at 10:45 am
Recipients
Dr. Amara Shalobi, MD
Owner
S
S. Rivera, RN
[Pathology Report – Doe, J. Lung Biopsy]
Blue Ridge Medical Center Pathology, Mar 8th 2026 at 3:50 pm
2
Replies
1
File
2
Recipients
Dr. Shalobi,
Attached is the pathology report for John Doe from the CT-guided biopsy on March 6th. The findings confirmed non-small cell lung carcinoma, adenocarcinoma type, with an EGFR exon 19 deletion and PD-L1 expression at 35%.
Full report with IHC staining and molecular panel is in the attachment. Please contact Dr. Osei at (864) 555-0137 with any questions.
2 Replies
Dr. Amara Shalobi replied· Mar 8th 2026 at 5:22 pm
Thank you. The EGFR exon 19 deletion is very actionable — I'll be presenting these findings at the tumor board on the 10th and will likely recommend osimertinib as first-line targeted therapy.
B
Blue Ridge Medical Center Pathology replied· Mar 9th 2026 at 8:05 am
Understood. Please let us know if you need any additional tissue analysis or confirmatory staining before the board meeting.
Reply to this conversation
1 File
Download all
PathReport_Doe_J_20260306.pdf (2.7 MB)
Added by Blue Ridge Medical Center Pathology on Mar 8th 2026 at 3:50 pm
Recipients
G
Blue Ridge Medical Center Pathology
Owner
Dr. Amara Shalobi, MD
[Tumor Board – March case presentation]
Dr. Amara Shalobi, Mar 5th 2026 at 8:30 am
1
Reply
3
Recipients
Dr. Opara, I'd like to submit a case for the March 10th Multidisciplinary Tumor Board. The patient is John Doe (GCC-204917) — NSCLC, adenocarcinoma, right lower lobe, EGFR exon 19 deletion confirmed on biopsy March 6th.
I'll have my slides and clinical summary submitted to [email protected] by end of day Friday. Looking forward to the discussion.
1 Reply
O
Dr. K. Opara replied· Mar 5th 2026 at 11:15 am
Confirmed for March 10th at 7:00 AM in Conference Room B. Dr. Mensah and I look forward to reviewing the case with you.
Reply to this conversation
Recipients
Dr. Amara Shalobi, MD
Owner
O
Dr. K. Opara, MD
M
Dr. A. Mensah, MD
[Clinical Trial Consent – Thompson, M.]
Dr. Amara Shalobi, Mar 3rd 2026 at 4:20 pm
1
Reply
1
File
2
Recipients
Hi Marcus, I've attached the KEYNOTE-789 clinical trial consent materials for you to review before your next visit. Please read through everything carefully — the attached PDF covers the full scope of participation, what to expect, and your rights as a participant.
There's no rush to decide, but if you have any questions after reading through it please don't hesitate to reach out. We can also go over everything together at your appointment.
1 Reply
M
M. Thompson replied· Mar 3rd 2026 at 6:15 pm
Thank you for sending this over. I've read through it and I'm ready to move forward. I have a few questions I'd like to go over at the appointment, mainly around the infusion schedule and monitoring.
Reply to this conversation
1 File
Download all
IRB_Consent_Thompson_M_KEYNOTE789.pdf (0.8 MB)
Added by Dr. Amara Shalobi on Mar 3rd 2026 at 4:20 pm
Recipients
Dr. Amara Shalobi, MD
Owner
M
M. Thompson
Message Options
Export to Inbox
Allow recipients to securely send a copy of this message to their regular email mailbox.
Protect Subject
Mask the subject line when used in unsecure notifications.
Open Notification
Send me a notification when a recipient first opens this message.
Message Password
Require recipients to enter a unique password to open this message.
Require recipients to enter a unique password to open this message.
Message Expiration
Set a time to make this message unavailable to recipients.
Set a time to make this message unavailable to recipients.
From the Trenches
Loved by MSPs. Loved by users.
There's no encryption platform that's easier to use than Bracket. We love the ease of setup and not having extra management steps. And users love the simplicity too.
Tim Knarr
The 20 MSP
The best part of Bracket is that it solved our biggest headache with encrypted email. Even our most challenging clients can use it without calling us every time.
Dick Borrelli
Newnan Computers
The end user training is literally dummy proof. You simply throw brackets around the subject. We also love that Bracket includes secure file transfer at no cost.
Aaron Gurgul
Watchdog Cyber
Frequently Asked Questions
How do I trigger Bracket to encrypt a message?
Bracket will trigger by default anytime there is a square bracket in the first value of the subject and a closing square bracket anywhere else in the subject. For example:
[Bracket works great]or[Bracket works] great—encrypts.Bracket is [not working] for me—doesn't.
The subject rule trigger can also be changed to {curly} or |pipes|.
What do senders and recipients need to get started?
Nothing. Senders use whatever email client and device they prefer. No apps, plugins or passwords are required. The Bracket portal opens in any browser, providing a clean and organized view of every encrypted conversation. Recipients access encrypted messages through a secure link without having to create an account, so there’s no friction on either end.
If there's no password, how is it secure?
Password reset emails are one of the most exploited attack vectors, and a source of a lot of support tickets. Bracket eliminates both obstacles. What replaces them is more secure, not less. AES-256 is just the beginning.
Sign-in links are one-time-use, expire after 15 minutes, and are invalidated if opened from a different device. Each request also carries an IP-based geolocation signature to flag unexpected access attempts.
For extra security, users can enable MFA at sign-in. For maximum control, personal data keys create a zero-access boundary. Note: personal data keys are shown only once at setup and never stored by Mailprotector. If they are misplaced, account recovery requires a full reset and all previously stored data will be irrecoverable.
Is Bracket HIPAA compliant?
Yes. Bracket meets HIPAA technical security safeguard standards for secure transmission of Electronic Protected Health Information (ePHI). Mailprotector holds the HIPAA Seal of Compliance from the Compliancy Group and is also SOC 2 Type 2 certified, providing independent verification of our security practices.
How long are Bracket messages retained?
Bracket messages are stored for one year by default and cannot be extended beyond that in accordance with the compliance retention requirements for most industries. For retention beyond one year, Bracket supports journaling to Mailprotector’s SecureStore™ or a third-party archiving service via SMTP journal or BCC addresses. Expiration can also be shortened on a per-message basis.
What email security solutions does Bracket work alongside?
Bracket is available as a standalone email encryption solution. For Microsoft 365 environments, it can also be deployed without changing MX records.
However, Bracket works best as part of the Mailprotector ecosystem. If you have configured your outbound relay through CloudFilter™, there’s no additional work to enable Bracket. Simply switch it on.
With Shield, Bracket becomes part of a deeper outbound security workflow via Email Traffic Control. Messages containing sensitive content can be automatically encrypted, adding a powerful layer of DLP at a fraction of the cost of a Microsoft E5 license.
Can Bracket be personalized?
Yes. Admins can configure a company profile—name, address, phone, website, and logo—that appears in Bracket notifications sent by any licensed user in the organization. This makes messages more recognizable to recipients and verifies the sender is authentic. Individual users can also personalize their own profile with a photo, name, and title. Admins control whether users can adjust company details from their own portal settings.
Every Bracket notification and message also includes a prompt for unlicensed recipients who may want to learn more about using Bracket in their own company. Those inquiries route to an email address you control—giving you a warm lead from someone who has already experienced Bracket firsthand.
What is Bracket Share and is there an additional charge?
Bracket Share is Mailprotector’s encrypted file transfer service, included with every Bracket license at no additional cost. It supports files up to 1GB, with up to 25 files per secure message. Anyone who regularly sends or receives sensitive files—whether that’s financial data, legal documents, or patient records—has a use for Bracket Share.
Ready to see painless email encryption in action?
Get a personalized walkthrough and bring your questions. We can’t wait to show you email encryption that actually gets used. Your bottom line will thank you.